+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The role of topical calcineurin inhibitors in atopic dermatitis



The role of topical calcineurin inhibitors in atopic dermatitis



British Journal of Dermatology 151 Suppl 70 Dec 2004: 3-27



For more than five decades, topical corticosteroids and emollients have been the mainstay of therapy for atopic dermatitis. However, the potential for side-effects limits the clinical utility of corticosteroids in providing long-term disease control. With a unique mode of action that differs from that of corticosteroids, the steroid-free topical calcineurin inhibitors (TCIs), tacrolimus ointment and pimecrolimus cream, provide skin-selective treatment that targets key factors involved in the pathogenesis of this chronic disease. An extensive series of clinical trials involving more than 16,000 patients with predominantly moderate to severe atopic dermatitis in tacrolimus studies and over 2000 patients with primarily mild to moderate disease in pimecrolimus studies has shown that both TCIs provide effective and well-tolerated treatment for atopic dermatitis. Randomized controlled trials have demonstrated that tacrolimus is superior to conventional hydrocortisone-based regimens and does not cause skin atrophy or other steroidal side-effects. Both tacrolimus and pimecrolimus prevent disease flares and provide progressive and sustained disease improvement with long-term therapy. These and other clinical benefits of TCIs are discussed, together with the safety profiles of tacrolimus and pimecrolimus and their use in clinical practice. In addition, this review summarizes findings from the many trials carried out with these agents and outlines how TCIs can provide long-term treatment and control of a chronic skin disease that may persist for years.

(PDF emailed within 0-6 h: $19.90)

Accession: 012680166

Download citation: RISBibTeXText

PMID: 15548171

DOI: 10.1111/j.1365-2133.2004.06269.x


Related references

Role of topical calcineurin inhibitors on atopic dermatitis of children. Current Medicinal Chemistry 14(14): 1579-1591, 2007

Role of Topical Calcineurin Inhibitors on Atopic Dermatitis of Children. Current Medicinal Chemistry 14(14): 1579-1591, 2007

The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. American Journal of Clinical Dermatology 8(3): 157-173, 2007

Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. American Journal of Therapeutics 16(3): 264-273, 2009

Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Current Medical Research and Opinion 24(4): 985-994, 2008

Topical Calcineurin Inhibitors in Pediatric Atopic Dermatitis. Pediatric Drugs 9(5): 289-299, 2007

Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology 5(4): 267-279, 2004

The treatment of atopic dermatitis in adults with topical calcineurin inhibitors. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 54(5): 424-431, 2003

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. PharmacoTherapy 27(7): 1020-1028, 2007

Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. Bmc Pediatrics 16: 75, 2017

Topical therapy: calcineurin inhibitors helpful in atopic dermatitis of dogs. Veterinary Times 37(45): 16, 2007

A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medgenmed 8(4): 8, 2007

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211(2): 174-187, 2005

Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. Journal of Dermatology 39(6): 520-526, 2012

Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. American Journal of Clinical Dermatology 7(4): 213-222, 2006